Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.
Köklü S, Tuna Y, Gülşen MT, Demir M, Köksal AŞ, Koçkar MC, Aygün C, Coban S, Ozdil K, Ataseven H, Akin E, Pürnak T, Yüksel I, Ataseven H, Ibiş M, Yildirim B, Nadir I, Küçükazman M, Akbal E, Yüksel O, Başar O, Alkan E, Baykal O. Köklü S, et al. Among authors: gulsen mt. Clin Gastroenterol Hepatol. 2013 Jan;11(1):88-94. doi: 10.1016/j.cgh.2012.10.003. Epub 2012 Oct 9. Clin Gastroenterol Hepatol. 2013. PMID: 23063679
Safety of peginterferon alfa-2a (40KD) treatment in patients with chronic hepatitis B infection: an observational, multicenter, open label, non-interventional study in Turkish patients.
Tözün N, Sezgın O, Gülşen M, Kacar S, Yenıce N, Yilmaz Ş, Hülagü S, Kantarçeken B, Yakaryilmaz F, Yurcı A, Serez KM, Bahçecıoğlu H, Bağci S. Tözün N, et al. Turk J Gastroenterol. 2012;23(5):552-9. Turk J Gastroenterol. 2012. PMID: 23161301 Free article. Clinical Trial.
Lamivudine treatment failure risks in chronic hepatitis B patients with low viral load.
Koklu S, Gulsen MT, Tuna Y, Koklu H, Yuksel O, Yilmaz B, Karaca C, Ataseven H, Guner R, Kucukazman M, Kockar C, Demir M, Poyrazoglu OK, Ibis M, Purnak T, Etgul S, Alkan E, Coban S, Gokturk S, Biyik M, Baykal O, Basar O, Koklu N, Tatar G, Simsek H. Koklu S, et al. Among authors: gulsen mt. Digestion. 2013;88(4):266-71. doi: 10.1159/000356312. Digestion. 2013. PMID: 24356645
Differences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis B.
Koklu S, Gulsen MT, Tuna Y, Koklu H, Yuksel O, Demir M, Guner R, Dogan Z, Kucukazman M, Poyrazoglu OK, Biyik M, Ozturk NA, Aydogan T, Coban S, Kocaman O, Sapmaz F, Gokturk SH, Karaca C, Demirezer A, Tanoglu A, Yildirim B, Altinbas A, Atak BM, Cosar AM, Alkan E; Other collaborators. Koklu S, et al. Among authors: gulsen mt. Aliment Pharmacol Ther. 2015 Feb;41(3):310-9. doi: 10.1111/apt.13036. Epub 2014 Dec 4. Aliment Pharmacol Ther. 2015. PMID: 25982037
Changes in Hepatitis C Awareness in Different Disciplines During COVID-19.
Barutçu S, Yıldırım Ç, Yıldırım AE, Konduk BT, Sayiner ZA, Gülşen MT. Barutçu S, et al. Among authors: gulsen mt. Turk J Gastroenterol. 2022 Oct;33(10):838-843. doi: 10.5152/tjg.2022.21726. Turk J Gastroenterol. 2022. PMID: 35946888 Free PMC article.
49 results